In conclusion, we identified the key gene to reveal the potential pathophysiology of LUAD and PAH and determined that G6PD is an immune-related biomarker and possible therapeutic target for LUAD and PAH patients. The gene discussed is G6PD; the disease is pulmonary arterial hypertension.